Table II.
DRI values for growth inhibition by paclitaxel/cisplatin/olaparib in combination for A2780 and OVCAR-3 cell lines.
| DRI | ||||||||
|---|---|---|---|---|---|---|---|---|
| Cell line | Combination | Component | 0.0625xIC50 | 0.125xIC50 | 0.25xIC50 | 0.5xIC50 | 1xIC50 | 2xIC50 |
| A2780 | Paclitaxel+Cisplatin | Paclitaxel | 0.75 | 2.29 | 1.89 | 1.53 | 1.17 | 0.70 |
| Cisplatin | 0.20 | 4.49 | 6.50 | 8.97 | 11.12 | 8.04 | ||
| Paclitaxel+Olaparib | Paclitaxel | 4.09 | 5.26 | 2.69 | 1.32 | 1.46 | 0.73 | |
| Olaparib | 1.89 | 12.73 | 6.74 | 3.18 | 14.15 | 7.07 | ||
| Cisplatin+Olaparib | Cisplatin | 13.83 | 26.11 | 11.27 | 6.34 | 5.74 | 4.36 | |
| Olaparib | 4.54 | 12.73 | 5.26 | 3.06 | 3.31 | 2.84 | ||
| OVCAR-3 | Paclitaxel+Cisplatin | Paclitaxel | 3.30 | 2.60 | 1.37 | 0.90 | 0.91 | 1.27 |
| Cisplatin | 4.07 | 3.11 | 1.63 | 1.06 | 1.02 | 1.33 | ||
| Paclitaxel+Olaparib | Paclitaxel | 1.51 | 1.91 | 1.45 | 0.64 | 0.90 | 1.01 | |
| Olaparib | 2.00 | 2.54 | 1.94 | 0.85 | 1.21 | 1.37 | ||
| Cisplatin+Olaparib | Cisplatin | 5.45 | 2.72 | 2.14 | 1.32 | 1.32 | 2.03 | |
| Olaparib | 6.02 | 3.01 | 2.45 | 1.53 | 1.62 | 2.72 | ||
The combined treatment was performed at the indicated fixed 1:1 ratio relative to their respective IC50 concentrations. DRI values were calculated from the DRI equation and algorithm using CompuSyn software. Favorable DRI values (>1.0) are highlighted in bold font. DRI, dose reduction index.